TrialEBioMedicine2025

Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.

Mary Lynn Baniecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.